**Name of journal:** *World Journal of Orthopedics*

**Manuscript no:** 55080

**Manuscript type:** MINIREVIEWS

**Current concepts in the surgical treatment of skeletal metastases**

Ehne J *et al*. Surgical treatment of skeletal metastases

Jessica Ehne, Panagiotis Tsagozis

**Jessica** **Ehne, Panagiotis** **Tsagozis,** Department of Orthopedic Surgery, Karolinska University Hospital, Solna 171 76, Sweden

**Author contributions:** Both Ehne J and Tsagozis P performed literature searches, contributed to the intellectual input and writing.

**Corresponding author:** **Jessica Ehne, MD, Surgeon,** Department of Orthopedic Surgery, Karolinska University Hospital, Eugeniavägen 3, Solna 171 76, Sweden. jessica.ehne@sll.se

**Received:** February 28, 2020

**Revised:** May 20, 2020

**Accepted:** May 30, 2020

**Published online:** July 18, 2020

**Abstract**

Symptomatic metastatic bone disease affects a large proportion of patients with malignant tumours and significantly impairs patients’ quality of life. There are still controversies regarding both surgical indications and methods, mainly because of the relatively few high-quality studies in this field. Generally, prosthetic reconstruction has been shown to result in fewer implant failures and should be preferred in patients with a good prognosis. Survival estimation tools should be used as part of preoperative planning. Adjuvant treatment, which relies on radiotherapy and inhibition of osteoclast function may also offer symptomatic relief and prevent implant failure. In this review we discuss the epidemiology, indications for surgery, preoperative planning, surgical techniques and adjuvant treatment of metastatic bone disease.

**Key words:** Pathological fracture; Bone cancer; Adjuvant radiotherapy; Survival analysis; Fracture fixations; Fixation devices; Orthopaedic

**Citation:** Ehne J, Tsagozis P. Current concepts in the surgical treatment of skeletal metastases. *World J Orthop* 2020; 11(7): 319-327

**URL:** https://www.wjgnet.com/2218-5836/full/v11/i7/319.htm

**DOI:** https://dx.doi.org/10.5312/wjo.v11.i7.319

**Core tip:** Patients with metastatic bone disease are a heterogenous group. Complication rates are higher than for the native fracture group. To avoid unnecessary complications, preoperative planning is crucial and allows correct surgical timing. Adjuvant treatment should be considered.

**INTRODUCTION**

The skeleton is the third most common site of metastasis, with breast, prostate and lung cancer accounting for 80% of bone metastases. The incidence of bone metastasis is uncertain, but post-mortem studies have reported incidences of 74% and 68% for breast and prostate cancer, respectively, and 28%-34% for lung, thyroid and kidney carcinomas[1,2]. Other neoplasms, such as gastrointestinal tract tumours are reported to rarely metastasize to the skeleton but there may be geographical differences[3]. In line with these post-mortem findings, The Scandinavian Sarcoma Group registry found that prostate, renal cell, lung cancer and myeloma accounted for 78% of surgically-treated bone tumours[4]. The most common site for bony metastases is the spine. In the appendicular skeleton, the femur is the most common site, followed by the humerus and then the tibia[3].

Symptomatic metastasis to bone is commonly referred to as metastatic bone disease (MBD). MBD can present with hypercalcaemia, bone pain, spinal cord or nerve root compression, impending or manifested fractures[1]. In cancer patients, bone pain is highly suggestive of bone metastases[4]. The exact number of patients living with MBD is unknown, but the number is expected to rise primarily due to the ageing population and the advancement in treatment of the most common cancer types[1,5]. MBD is painful and has a significant negative effect on quality of life, the negative effects can be improved with surgery[6]. Most patients with MBD are palliative. Median survival from diagnosis of bone metastasis ranges from 6 mo in lung cancer and melanoma, to 12-53 mo in prostate cancer and 19-48 mo in breast cancer[4]. Reflecting this, median postoperative survival is, depending on the primary cancer, 3-12 mo[7].

Despite the fact that MBD severely affects a large group of palliative patients and is a driver of overall oncology cost[8], research is scarce and mainly consists of retrospective case series which are heterogenous and difficult to draw conclusions from. Solid evidence is lacking in almost every field, from surgical management to adjuvant treatment[9-12].

As the main symptoms of metastatic bone disease are pain, loss of mechanical function due to instability, and neurological compromise, the goal of surgery is to provide pain relief, restore biomechanical stability and potential neurological compromise. Nonsurgical treatments such as radiotherapy, chemotherapy or local tumour ablation are almost never effective in relieving pain associated with biomechanical insufficiency and instability related to pathological fractures. Another important axiom is that treatment of pathological fractures cannot rely on bone healing as these fractures rarely ever heal.

Surgical reconstruction should be stable enough to last the often, short lifetime of the patient and allow for immediate mobilization, anything less than that should be considered a surgical failure. As the point of best skeletal stability is achieved directly after surgery in most cases, orthoses, braces or other devices meant to support the surgical fixation should not be used.

**INDICATION FOR SURGICAL TREATMENT**

The decision to operate on a metastatic bone lesion, with or without a pathological fracture is not always easy. Complete pathological fractures in the long bones of the upper or lower extremity, especially the femur and the humerus, are almost always treated surgically as this is the only way to allow for patient mobilization and adequate pain relief. Non-surgical treatment in these cases is reserved for patients that are in a late terminal stage of their disease. On the other hand, complete pathological fractures in flat bones of the axial skeleton, such as the ribs, the innominate bones of the pelvis, the sternum and the scapula are almost never treated with surgery.

Pathological fractures of the spine are treated in the general context of metastatic spinal disease, the degree and characteristics of the neurological impairment together with the overall condition of the patient and the expected oncological outcome are the primary factors taken into account in the choice of treatment. Patients with severe, but not complete neurological deficits, those with recent onset of symptoms and those with good prognosis are the most likely to benefit from surgery. Clinically useful staging systems are available in order to select patients for surgical treatment[13-15]. There has been a considerable shift towards surgical treatment in the past decades, with evidence showing a clear benefit in the neurological outcome of patients treated with surgery which may also have an implication for survival[16].

Fractures of the small bones of the hand and foot are extremely rare and there are very few data regarding their treatment[17,18]. When treating patients with impending fractures the surgical indications are relative. A combination of prediction of future fracture risk, severity of clinical symptoms, location and extent of the lesion, expected patient survival and the potential harm of failed surgery should be carefully considered. As an exception, bone metastasis from haematological malignancy without any obvious pathological fracture should preferably be treated non-surgically. These neoplasms are usually highly radiosensitive and tend to respond quickly to chemotherapy. The indication for surgical treatment is a complex decision-making process and reflects the considerably high variation in practice among different clinics and regions[19].

To expedite decision-making, several algorithms have been developed, regarding both the characteristics of the lesion as well as the expected survival of the patient. One of the most commonly used algorithms is the classification introduced by Mirels for predicting fracture risk[20]. The original study is limited by a small study base, consisting of mainly breast cancer patients. It is still widely used but is rather obsolete[21,22]. For a more reliable prediction of fracture risk, computed tomography (CT) based measures of structural stability can be used[23]. If CT scans are not readily available, a newly developed model that requires nothing more than a scale for predicting impending fractures of the lower extremity through single stance weight bearing has been suggested by Howard *et al*. However, this method still needs external validation[24].

Another critical parameter in the decision to proceed to surgery is the expected patient survival. Certain metastatic lesions in the axial skeleton, for example spinal metastases, are probably not amenable to surgical treatment if estimated patient survival is poor, generally less than 3 mo. The development of algorithms to be used as tools in order to predict survival has been a significant achievement in this field, making predictions much more accurate, and considerably facilitates the task of the treating physician.

**METHODS AND OUTCOME OF SURGICAL TREATMENT**

The surgical method and the implant to be used should be chosen wisely. As a rule of thumb, the longer the expected survival of the patient, the more extensive the surgery.

In patients with a particularly good survival prognosis such as those with solitary metastases from breast cancer or renal cell carcinoma, en bloc resection and reconstruction with a tumour prosthesis is justified as these tumours have a lower risk of relapse. En bloc resection in these cases is also associated with improved survival[19,25].

Doctors are known to overestimate when predicting survival. As discussed in the previous paragraph, precision in estimation is critical in selecting patients who will benefit from surgery and is essential for preoperative planning[26,27]. Estimating survival and correlating choice of implant to survival estimates, prevents too extensive surgery and rehabilitation in patients with short survival and an unacceptably high implant failure rate in those who live longer. As externally validated survival models that are free to use exist, there are no reasons not to do so[28-31,32]. There are generally three treatment strategies: osteosynthesis, prosthetic reconstruction or local excision with or without reconstruction (*i.e.*, curettage with or without cementation, cementoplasty, excision arthroplasty, resection of a bone segment or amputation).

***Surgical treatment of metastases in the appendicular skeleton***

In the long bones, surgery is recommended even when estimated survival is as short as two-six weeks[33]. The whole bone should be examined radiologically preoperatively, and this can be performed with plain radiographs or a CT-scan. In the long bones, the femur is the commonest site of MBD, and the proximal femur is the most common site for pathological fractures in the femur. Unlike in native fractures of the proximal femur, delayed time to surgery > 48 h does not seem to affect postoperative complication rate, further strengthening the hypothesis that careful preoperative planning should be undertaken in these patients[34]*.* The implant of choice when performing surgeries of the femoral neck is an endoprosthesis. Only if the patient is deemed unfit for prosthesis-surgery, a percutaneous screw fixation may be considered, occasionally with cement reinforcement.

In the trochanteric region, intramedullary nails (IM-nails), conventional prostheses or tumour prostheses can be used. As complications related to non-union and tumour growth such as implant breakage and loosening tend to occur 6-12 mo postoperatively, in patients with a shorter estimated survival (3-6 mo), IM-nailing is adequate[10,12,35,36]. However, IM-nails should not be used if there is tumour mass affecting the neck of the femur, even if the fracture itself is in the intertrochanteric region. A large nail diameter adds mechanical stability and reduces the risk of implant breakage, providing the patient with a better chance of early pain reduction. Because of this, we believe that proper reaming should always be done despite the added cardiovascular risk.

In the proximal femur, prosthesis surgery is associated with better functional outcomes and a lower risk of revision surgery[33]. However, it is associated with a higher risk of systemic complications in the postoperative period due to surgical trauma and generally requires a longer period of rehabilitation. Due to this, prosthesis surgery is generally reserved for patients with a longer estimated survival. When there are no clinical signs of osteoarthritis a hemiarthroplasty is often sufficient. Total hip replacement poses a higher risk of dislocation and is associated with longer operating times and thus perioperative risks[37]. However, the only study published so far comparing morbidity and mortality between hemiarthroplasty and total hip replacement in MBD patients found no difference in short-term morbidity and mortality[33].

In the femoral diaphysis, IM-nails are preferred, provided there is sufficient bone stock. Osteosynthesis with long plates are also used. There is seldom the need for more advanced reconstructions, such as intercalary prostheses which are reserved for patients with excellent prognosis only. MBD of the distal third of the femur can be managed with osteosynthesis, and adjuvant bone cement is often needed due to poor bone quality in this region. Other options are conventional cemented knee arthroplasty for lesions restricted to the subchondral area or tumour prosthesis for larger lesions[38].

Despite the fact that that prosthesis surgery is the preferred surgical method for patients with a life expectancy of more than 6 mo, treatment of a lesion in the upper metaphyseal region and the life expectancy of MBD patients is possibly increasing. Varady *et al* found a trend towards the increased use of IM-nails in patients operated between 2009-2017, indicating a possible change in general treatment strategies[39].

The humerus is the second most common site for MBD of the long bones[9]. Standard surgical options are the same as for the femur. As the humerus is not a weight bearing bone, the primary surgical indication should be residual pain after radiotherapy or a complete fracture with significant symptoms. In the upper metaphysis of the humerus, plates and screws with cement augmentation as needed or prosthesis surgery can be used, with prosthesis surgery being preferred for patients with large bone destruction or a longer life expectancy. In the meta-diaphysis or diaphysis region of the humerus, the most common implants of choice are IM-nails or plate and screw fixation, with cement if needed. In the humerus, pathological fractures of the diaphysis are the most common reason for surgery. As in the femur, IM nailing and prosthesis surgery have the lowest reported reoperation rates and most reoperations are due to non-union, with an increasing complication rate over time[37,39]. The distal third of the humerus accounts for the highest complication rates[37]. Tertiary centres should preferably be consulted in these cases and patients transferred as decisions regarding surgical options and adjuvant treatment are best handled by experienced surgeons.

***Surgical treatment of metastases in the axial skeleton***

Regarding pathological fractures of the axial skeleton, surgery is mainly indicated in cases of acetabular involvement or spinal metastasis. When the acetabulum is affected by MBD there is usually significant pain at ambulation. When protrusion of the femoral head occurs, the joint may be locked prohibiting even sitting in a wheelchair. Non-surgical treatment is not efficient in relieving such biomechanical symptoms. Surgery may entail a simple excision arthroplasty in patients with very poor general condition or terminal disease. Cementoplasty may be considered in constrained, relatively small lytic periacetabular lesions without any displaced pathological fracture[40,41]. In relatively small defects that are not contained, and extend to the hip joint, curettage and a cemented total hip arthroplasty are sufficient. When there is a displaced fracture and the general condition of the patient allows, more advanced reconstruction may be necessary. The general principle is the transfer of the biomechanical load from the proximal femur to the intact pelvic bone. This can be achieved using an anti-protrusion acetabular cage with screws placed in an antegrade or retrograde mode[42,43]. When there is extensive bone loss prohibiting the aforementioned technique, the skeletal defect may be bridged using a pelvic prosthesis (usually an ice-coned device) that is docked to the remaining intact pelvic bone, a technique which usually requires adequate bone stock around the posterior iliac bone[44]. In extreme cases of bone loss, the implant may be inserted in the sacrum. The outcome of surgical treatment of acetabular lesions is generally good, with most patients regaining ambulatory capacity and experiencing pain relief. However, the complication rate in this area is also significant, with dislocations of the prostheses being common, probably due to the insufficient bone stock which prevents optimal placing of the implants. Furthermore, infections are also frequent, due both to the microbial flora of the area and the bulky implants used.

In metastatic spinal disease, the most common method of surgical treatment is posterior decompression (laminectomy), with or without posterior fixation with pedicle screws and rods[45]. Although metastatic spinal disease generally involves the spinal body rather than the posterior elements, and anterior decompression should theoretically be advantageous, posterior-only approaches have been shown to be equally effective. When there is no pathological fracture of the involved vertebra, decompression is generally sufficient. In cases of pathological fracture with biomechanical instability, posterior fixation is recommended, especially when the expected survival is longer than 6 mo. The functional outcome of surgery for metastatic spinal disease has been shown to be superior to treatment with radiotherapy only, and the majority of patients experience improvement of neurological function and regain the ability to ambulate[16,46]. There is also evidence that these patients have longer survival which may be attributed to rapid mobilization. Common complications in this area are infections, since there is generally poor soft-tissue coverage especially in the thoracic spine, which is the most common area for metastatic spinal disease in cancer patients.

**ADJUVANT TREATMENT OF METASTATIC BONE DISEASE**

Single therapy low dose radiotherapy (RT) provides good pain relief in most MBD patients and is often the first line of treatment[47]. However, preoperative RT has been associated with higher complication rates[19,37]. Postoperative RT is widely used with the intention to decrease the risk of metastatic growth and subsequent implant loosening, loss of function and pain. As pointed out in a review article on the subject by Willeumier *et al*, this practice is possibly harmful as postoperative RT theoretically could inhibit soft tissue healing and evidence of its beneficial effects are scarce and mainly based on one retrospective cohort study[11,48].

Inhibition of osteoclast activity is a well-established method to prevent skeletal events, such as pathological fractures, in patients with MBD. Bisphosphonates have been the standard of care since the late 1990s, with zoledronate showing the most potent effect. Besides their direct inhibition of osteoclast activity, other mechanisms such as stimulation of innate immune cells have been proposed to explain their observed effect on patient survival. Their use is best documented in breast and hormone-resistant prostate cancer[48]. A significant achievement during the past decade has been the introduction of denosumab, a monoclonal antibody against RANKL which directly blocks osteoclast activity and is less nephrotoxic than bisphosphonates[49]. Current guidelines describe the indication for the use of these agents in order to prevent skeletal-related events such as pathological fractures. However, their effect on the outcome of surgical treatment of these fractures has to our knowledge not been investigated[48]. Theoretically, they may prevent progression of osteolytic lesions after surgical treatment, or even promote consolidation of the lesion, analogous to the effect denosumab has on giant cell tumours of the bone.

Percutaneous image-guided interventions, such as embolization and thermal ablation of bone metastases are also available. Embolization of feeding vessels may considerably facilitate surgery of a metastatic bone lesion, especially in central locations such as the pelvis and spine[50]. Certain primary tumours such as renal cancers are well-known for their propensity to bleed profusely. Pre-operative embolization can reduce the associated morbidity and allow for a better surgical outcome. Thermal ablation, most often radiofrequency ablation or cryoablation, is used when open surgical treatment is contraindicated. It relies on a direct thermal effect destroying the malignant cells[51,52].

Bone cement has also been shown to have a thermal effect on tumour cells due to the exothermal polymerization reaction. Its use is common in surgery for MBD, both in cases of osteosynthesis as well as during endoprosthetic reconstruction. In the former case, cement provides structural support after curettage of the bone lesion. Furthermore, it can be used separately to mechanically reinforce the bone in cases of constrained lytic metastatic lesions (cementoplasty), commonly in the spine or acetabulum. Despite its vast use in surgery for MBD, whether the use of bone cement contributes to a decreased risk of surgical failure has not been established.

**CONCLUSION**

MBD is still indicative of end-stage cancer and for most patients also bone pain and possibly fractures. Orthopaedic surgery is effective in reducing pain and restoring ambulatory capacity in these palliative patients but must be carefully planned to avoid causing unnecessary harm. Patients with complicated fractures, especially of the distal ends of the long bones should be referred to tertiary centres, as should patients with single or oligometastases and a very long life expectancy in whom en bloc resection of the tumour might be beneficial. High quality research is still lacking, probably due to the practical difficulties of performing prospectively randomized studies in this palliative study group.

**REFERENCES**

1 **Coleman RE**. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. *Cancer Treat Rev* 2001; **27**: 165-176 [PMID: 11417967 DOI: 10.1053/ctrv.2000.0210]

2 **Coleman RE**. Clinical features of metastatic bone disease and risk of skeletal morbidity. *Clin Cancer Res* 2006; **12**: 6243s-6249s [PMID: 17062708 DOI: 10.1158/1078-0432.CCR-06-0931]

3 **Wisanuyotin T**, Sirichativapee W, Sumnanoont C, Paholpak P, Laupattarakasem P, Sukhonthamarn K, Kosuwon W. Prognostic and risk factors in patients with metastatic bone disease of an upper extremity. *J Bone Oncol* 2018; **13**: 71-75 [PMID: 30591860 DOI: 10.1016/j.jbo.2018.09.007]

4 **Selvaggi G**, Scagliotti GV. Management of bone metastases in cancer: a review. *Crit Rev Oncol Hematol* 2005; **56**: 365-378 [PMID: 15978828 DOI: 10.1016/j.critrevonc.2005.03.011]

5 **Biermann JS**, Holt GE, Lewis VO, Schwartz HS, Yaszemski MJ. Metastatic bone disease: diagnosis, evaluation, and treatment. *J Bone Joint Surg Am* 2009; **91**: 1518-1530 [PMID: 19487533]

6 **Malviya A**, Gerrand C. Evidence for orthopaedic surgery in the treatment of metastatic bone disease of the extremities: a review article. *Palliat Med* 2012; **26**: 788-796 [PMID: 21930647 DOI: 10.1177/0269216311419882]

7 **Ratasvuori M**, Wedin R, Keller J, Nottrott M, Zaikova O, Bergh P, Kalen A, Nilsson J, Jonsson H, Laitinen M. Insight opinion to surgically treated metastatic bone disease: Scandinavian Sarcoma Group Skeletal Metastasis Registry report of 1195 operated skeletal metastasis. *Surg Oncol* 2013; **22**: 132-138 [PMID: 23562148 DOI: 10.1016/j.suronc.2013.02.008]

8 **Schulman KL**, Kohles J. Economic burden of metastatic bone disease in the U.S. *Cancer* 2007; **109**: 2334-2342 [PMID: 17450591 DOI: 10.1002/cncr.22678]

9 **Kendal JK**, Abbott A, Kooner S, Johal H, Puloski SKT, Monument MJ. A scoping review on the surgical management of metastatic bone disease of the extremities. *BMC Musculoskelet Disord* 2018; **19**: 279 [PMID: 30081884 DOI: 10.1186/s12891-018-2210-8]

10 **Willeumier JJ**, van der Linden YM, van de Sande MAJ, Dijkstra PDS. Treatment of pathological fractures of the long bones. *EFORT Open Rev* 2016; **1**: 136-145 [PMID: 28461940 DOI: 10.1302/2058-5241.1.000008]

11 **Willeumier JJ**, van der Linden YM, Dijkstra PD. Lack of clinical evidence for postoperative radiotherapy after surgical fixation of impending or actual pathologic fractures in the long bones in patients with cancer; a systematic review. *Radiother Oncol* 2016; **121**: 138-142 [PMID: 27524407 DOI: 10.1016/j.radonc.2016.07.009]

12 **Errani C**, Mavrogenis AF, Cevolani L, Spinelli S, Piccioli A, Maccauro G, Baldini N, Donati D. Treatment for long bone metastases based on a systematic literature review. *Eur J Orthop Surg Traumatol* 2017; **27**: 205-211 [PMID: 27650452 DOI: 10.1007/s00590-016-1857-9]

13 **Westermann L**, Olivier AC, Samel C, Eysel P, Herren C, Sircar K, Zarghooni K. Analysis of seven prognostic scores in patients with surgically treated epidural metastatic spine disease. *Acta Neurochir (Wien)* 2020; **162**: 109-119 [PMID: 31781995 DOI: 10.1007/s00701-019-04115-9]

14 **Carrwik C**, Olerud C, Robinson Y. Predictive Scores Underestimate Survival of Patients With Metastatic Spine Disease: A Retrospective Study of 315 Patients in Sweden. *Spine (Phila Pa 1976)* 2020; **45**: 414-419 [PMID: 31651680 DOI: 10.1097/BRS.0000000000003289]

15 **Choi D**, Ricciardi F, Arts M, Buchowski JM, Bunger C, Chung CK, Coppes M, Depreitere B, Fehlings M, Kawahara N, Leung Y, Martin-Benlloch A, Massicotte E, Mazel C, Meyer B, Oner C, Peul W, Quraishi N, Tokuhashi Y, Tomita K, Ulbricht C, Verlaan JJ, Wang M, Crockard A. Prediction Accuracy of Common Prognostic Scoring Systems for Metastatic Spine Disease: Results of a Prospective International Multicentre Study of 1469 Patients. *Spine (Phila Pa 1976)* 2018; **43**: 1678-1684 [PMID: 30422958 DOI: 10.1097/BRS.0000000000002576]

16 **Patchell RA**, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, Mohiuddin M, Young B. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. *Lancet* 2005; **366**: 643-648 [PMID: 16112300 DOI: 10.1016/S0140-6736(05)66954-1]

17 **Morris G**, Evans S, Stevenson J, Kotecha A, Parry M, Jeys L, Grimer R. Bone metastases of the hand. *Ann R Coll Surg Engl* 2017; **99**: 563-567 [PMID: 28853594 DOI: 10.1308/rcsann.2017.0096]

18 **El Abiad JM**, Aziz K, Levin AS, McCarthy EM, Morris CD. Osseous Metastatic Disease to the Hands and Feet. *Orthopedics* 2019; **42**: e197-e201 [PMID: 30602048 DOI: 10.3928/01477447-20181227-04]

19 **Ratasvuori M**, Wedin R, Hansen BH, Keller J, Trovik C, Zaikova O, Bergh P, Kalen A, Laitinen M. Prognostic role of en-bloc resection and late onset of bone metastasis in patients with bone-seeking carcinomas of the kidney, breast, lung, and prostate: SSG study on 672 operated skeletal metastases. *J Surg Oncol* 2014; **110**: 360-365 [PMID: 24889389 DOI: 10.1002/jso.23654]

20 **Mirels H**. Metastatic disease in long bones: A proposed scoring system for diagnosing impending pathologic fractures. 1989. *Clin Orthop Relat Res* 2003; : S4-13 [PMID: 14600587 DOI: 10.1097/01.blo.0000093045.56370.dd]

21 **Howard EL**, Shepherd KL, Cribb G, Cool P. The validity of the Mirels score for predicting impending pathological fractures of the lower limb. *Bone Joint J* 2018; **100-B**: 1100-1105 [PMID: 30062934 DOI: 10.1302/0301-620X.100B8.BJJ-2018-0300.R1]

22 **Van der Linden YM**, Dijkstra PD, Kroon HM, Lok JJ, Noordijk EM, Leer JW, Marijnen CA. Comparative analysis of risk factors for pathological fracture with femoral metastases. *J Bone Joint Surg Br* 2004; **86**: 566-573 [PMID: 15174555]

23 **Damron TA**, Nazarian A, Entezari V, Brown C, Grant W, Calderon N, Zurakowski D, Terek RM, Anderson ME, Cheng EY, Aboulafia AJ, Gebhardt MC, Snyder BD. CT-based Structural Rigidity Analysis Is More Accurate Than Mirels Scoring for Fracture Prediction in Metastatic Femoral Lesions. *Clin Orthop Relat Res* 2016; **474**: 643-651 [PMID: 26169800 DOI: 10.1007/s11999-015-4453-0]

24 **Howard EL**, Cool P, Cribb GL. Prediction of pathological fracture in patients with metastatic disease of the lower limb. *Sci Rep* 2019; **9**: 14133 [PMID: 31575994 DOI: 10.1038/s41598-019-50636-9]

25 **Krishnan CK**, Kim HS, Yun JY, Cho HS, Park JW, Han I. Factors associated with local recurrence after surgery for bone metastasis to the extremities. *J Surg Oncol* 2018; **117**: 797-804 [PMID: 29044578 DOI: 10.1002/jso.24880]

26 **Viganò A**, Dorgan M, Bruera E, Suarez-Almazor ME. The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancer. *Cancer* 1999; **86**: 170-176 [PMID: 10391577]

27 **Chow E**, Harth T, Hruby G, Finkelstein J, Wu J, Danjoux C. How accurate are physicians' clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review. *Clin Oncol (R Coll Radiol)* 2001; **13**: 209-218 [PMID: 11527298 DOI: 10.1053/clon.2001.9256]

28 **Sørensen MS**, Gerds TA, Hindsø K, Petersen MM. External Validation and Optimization of the SPRING Model for Prediction of Survival After Surgical Treatment of Bone Metastases of the Extremities. *Clin Orthop Relat Res* 2018; **476**: 1591-1599 [PMID: 30020148 DOI: 10.1097/01.blo.0000534678.44152.ee]

29 **Forsberg JA**, Eberhardt J, Boland PJ, Wedin R, Healey JH. Estimating survival in patients with operable skeletal metastases: an application of a bayesian belief network. *PLoS One* 2011; **6**: e19956 [PMID: 21603644 DOI: 10.1371/journal.pone.0019956]

30 **Katagiri H**, Okada R, Takagi T, Takahashi M, Murata H, Harada H, Nishimura T, Asakura H, Ogawa H. New prognostic factors and scoring system for patients with skeletal metastasis. *Cancer Med* 2014; **3**: 1359-1367 [PMID: 25044999 DOI: 10.1002/cam4.292]

31 **Willeumier JJ**, van der Linden YM, van der Wal CWPG, Jutte PC, van der Velden JM, Smolle MA, van der Zwaal P, Koper P, Bakri L, de Pree I, Leithner A, Fiocco M, Dijkstra PDS. An Easy-to-Use Prognostic Model for Survival Estimation for Patients with Symptomatic Long Bone Metastases. *J Bone Joint Surg Am* 2018; **100**: 196-204 [PMID: 29406340 DOI: 10.2106/JBJS.16.01514]

32 **Meares C**, Badran A, Dewar D. Prediction of survival after surgical management of femoral metastatic bone disease - A comparison of prognostic models. *J Bone Oncol* 2019; **15**: 100225 [PMID: 30847272 DOI: 10.1016/j.jbo.2019.100225]

33 **Varady NH**, Ameen BT, Hayden BL, Yeung CM, Schwab PE, Chen AF. Short-Term Morbidity and Mortality After Hemiarthroplasty and Total Hip Arthroplasty for Pathologic Proximal Femur Fractures. *J Arthroplasty* 2019; **34**: 2698-2703 [PMID: 31279601 DOI: 10.1016/j.arth.2019.06.019]

34 **Varady NH**, Ameen BT, Chen AF. Is Delayed Time to Surgery Associated with Increased Short-term Complications in Patients with Pathologic Hip Fractures? *Clin Orthop Relat Res* 2020; **478**: 607-615 [PMID: 31702689 DOI: 10.1097/CORR.0000000000001038]

35 **Steensma M**, Healey JH. Trends in the surgical treatment of pathologic proximal femur fractures among Musculoskeletal Tumor Society members. *Clin Orthop Relat Res* 2013; **471**: 2000-2006 [PMID: 23247815 DOI: 10.1007/s11999-012-2724-6]

36 **Chafey DH**, Lewis VO, Satcher RL, Moon BS, Lin PP. Is a Cephalomedullary Nail Durable Treatment for Patients With Metastatic Peritrochanteric Disease? *Clin Orthop Relat Res* 2018; **476**: 2392-2401 [PMID: 30299285 DOI: 10.1097/CORR.0000000000000523]

37 **Wedin R**, Bauer HC, Wersäll P. Failures after operation for skeletal metastatic lesions of long bones. *Clin Orthop Relat Res* 1999; 358: 128-139 [PMID: 9973984]

38 **Willeumier JJ**, van der Wal CWPG, Schoones JW, van der Wal RJ, Dijkstra PDS. Pathologic fractures of the distal femur: Current concepts and treatment options. *J Surg Oncol* 2018; **118**: 883-890 [PMID: 30328621 DOI: 10.1002/jso.25218]

39 **Varady NH**, Ameen BT, Schwab PE, Yeung CM, Chen AF. Trends in the surgical treatment of pathological proximal femur fractures in the United States. *J Surg Oncol* 2019; **120**: 994-1007 [PMID: 31407350 DOI: 10.1002/jso.25669]

40 **Kurup AN**, Schmit GD, Atwell TD, Sviggum EB, Castaneda WR, Rose PS, Callstrom MR. Palliative Percutaneous Cryoablation and Cementoplasty of Acetabular Metastases: Factors Affecting Pain Control and Fracture Risk. *Cardiovasc Intervent Radiol* 2018; **41**: 1735-1742 [PMID: 29881934 DOI: 10.1007/s00270-018-1998-9]

41 **Colman MW**, Karim SM, Hirsch JA, Yoo AJ, Schwab JH, Hornicek FJ, Raskin KA. Percutaneous Acetabuloplasty Compared With Open Reconstruction for Extensive Periacetabular Carcinoma Metastases. *J Arthroplasty* 2015; **30**: 1586-1591 [PMID: 26115981 DOI: 10.1016/j.arth.2015.02.022]

42 **Tsagozis P**, Wedin R, Brosjö O, Bauer H. Reconstruction of metastatic acetabular defects using a modified Harrington procedure. *Acta Orthop* 2015; **86**: 690-694 [PMID: 26220078 DOI: 10.3109/17453674.2015.1077308]

43 **Wegrzyn J**, Malatray M, Al-Qahtani T, Pibarot V, Confavreux C, Freyer G. Total Hip Arthroplasty for Periacetabular Metastatic Disease. An Original Technique of Reconstruction According to the Harrington Classification. *J Arthroplasty* 2018; **33**: 2546-2555 [PMID: 29656965 DOI: 10.1016/j.arth.2018.02.096]

44 **Guzik G**. The Use of LUMIC Prosthesis for the Treatment of Periacetabular Metastases. *Ortop Traumatol Rehabil* 2015; **17**: 593-602 [PMID: 27053391 DOI: 10.5604/15093492.1193013]

45 **Kato S**, Hozumi T, Takeshita K, Kondo T, Goto T, Yamakawa K. Neurological recovery after posterior decompression surgery for anterior dural compression in paralytic spinal metastasis. *Arch Orthop Trauma Surg* 2012; **132**: 765-771 [PMID: 22327407 DOI: 10.1007/s00402-012-1475-x]

46 **Chong S**, Shin SH, Yoo H, Lee SH, Kim KJ, Jahng TA, Gwak HS. Single-stage posterior decompression and stabilization for metastasis of the thoracic spine: prognostic factors for functional outcome and patients' survival. *Spine J* 2012; **12**: 1083-1092 [PMID: 23168136 DOI: 10.1016/j.spinee.2012.10.015]

47 **Chow R**, Hoskin P, Hollenberg D, Lam M, Dennis K, Lutz S, Lam H, Mesci A, DeAngelis C, Chan S, Chow E. Efficacy of single fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review and meta-analysis. *Ann Palliat Med* 2017; **6**: 125-142 [PMID: 28249544 DOI: 10.21037/apm.2016.12.04]

48 **Coleman R**, Body JJ, Aapro M, Hadji P, Herrstedt J; ESMO Guidelines Working Group. Bone health in cancer patients: ESMO Clinical Practice Guidelines. *Ann Oncol* 2014; **25 Suppl 3**: iii124-iii137 [PMID: 24782453 DOI: 10.1093/annonc/mdu103]

49 **Fizazi K**, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. *Lancet* 2011; **377**: 813-822 [PMID: 21353695 DOI: 10.1016/S0140-6736(10)62344-6]

50 **Owen RJ**. Embolization of musculoskeletal bone tumors. *Semin Intervent Radiol* 2010; **27**: 111-123 [PMID: 21629401 DOI: 10.1055/s-0030-1253510]

51 **Colangeli S**, Parchi P, Andreani L, Beltrami G, Scoccianti G, Sacchetti F, Ceccoli M, Totti F, Campanacci DA, Capanna R. Cryotherapy efficacy and safety as local therapy in surgical treatment of musculoskeletal tumours. A retrospective case series of 143 patients. *J Biol Regul Homeost Agents* 2018; **32**: 65-70 [PMID: 30644284]

52 **Zhao W**, Wang H, Hu JH, Peng ZH, Chen JZ, Huang JQ, Jiang YN, Luo G, Yi GF, Shen J, Gao BL. Palliative pain relief and safety of percutaneous radiofrequency ablation combined with cement injection for bone metastasis. *Jpn J Clin Oncol* 2018; **48**: 753-759 [PMID: 29931084 DOI: 10.1093/jjco/hyy090]

**Footnotes**

**Conflict-of-interest statement:** No conflicts of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 28, 2020

**First decision:** April 29, 2020

**Article in press:** May 30, 2020

**Specialty type:** Orthopedics

**Country/Territory of origin:** Sweden

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Xu GY **S-Editor:** Wang J **L-Editor:** Webster JR **E-Editor:**

**Figure Legends**

![[Image description]]()

**Figure 1 Multiple bone metastases in the femur of a patient with an estimated survival of 4 mo.** Intramedullary nailing with a long intramedullary nail. The patient was able to mobilize immediately and there were no re-operations.



**Figure 2 Solitary osteolytic lung cancer metastasis.** A: Solitary osteolytic lung cancer metastasis of the trochanteric region of the left femur in a 63-year-old female, with expected survival of approximately 1 year; B: Curettage of the lesion and reconstruction with a cemented hemiarthroplasty.